Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 193 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Flu Vaccine (Year 2) Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age

NCT00952705
View directory record Official record
Conditions
Healthy or Stable Underlying Chronic Medical Condition
Interventions
Q/LAIV-BFS (MEDI8662), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
18
States / cities
Mobile, Alabama • Sacramento, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

NCT05868382
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1010, mRNA-1010.4, mRNA-1010.6
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
10
States / cities
Hollywood, Florida • Miami, Florida • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Flublok or Fluzone With Advax-CpG55.2 or AF03

NCT03945825
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

NCT06508320
View directory record Official record
Conditions
Influenza, SARS-CoV-2
Interventions
mRNA-1083
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 64 Years
Enrollment
931 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
12
States / cities
Hialeah, Florida • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

NCT05874713
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

NCT05875961
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist

NCT00231907
View directory record Official record
Conditions
Influenza
Interventions
FluMist, Fluzone
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 35 Months
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
3
States / cities
St Louis, Missouri • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

NCT05945485
View directory record Official record
Conditions
Influenza
Interventions
DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

NCT03308825
View directory record Official record
Conditions
Influenza, Flu
Interventions
Fluzone Quadrivalent vaccine, Fluzone High-Dose vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Council Bluffs, Iowa • Bardstown, Kentucky • Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

NCT01560793
View directory record Official record
Conditions
Influenza
Interventions
VAX161 [STF2.HA5 H5N1]
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age

NCT00158665
View directory record Official record
Conditions
Influenza
Interventions
2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
5 Years to 8 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

NCT02207413
View directory record Official record
Conditions
Influenza
Interventions
Influsplit Tetra™ vaccine produced by investigational process (IP), Influsplit Tetra™ vaccine produced by licensed process (LP)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 49 Years
Enrollment
1,886 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Wichita, Kansas • Rochester, New York • Warwick, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

NCT06038617
View directory record Official record
Conditions
Fever After Vaccination, Fever, Seizures Fever
Interventions
mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Months to 4 Years
Enrollment
347 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
5
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

NCT02831751
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain), Fluzone® High-Dose (60 µg/strain)
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
1,001 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
6
States / cities
Redding, California • Hollywood, Florida • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

NCT05045144
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,586 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 11, 2026, 5:01 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

NCT02385123
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Vaccine Inactivated
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 11, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

NCT03658629
View directory record Official record
Conditions
Influenza, Human
Interventions
NanoFlu (Quad-NIV), Matrix-M Adjuvant, Placebo, Fluzone HD, Flublok Quadrivalent, Influenza Vaccine
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
65 Years and older
Enrollment
1,375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
14
States / cities
Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

NCT04789577
View directory record Official record
Conditions
Influenza, Human
Interventions
FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
8
States / cities
Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

NCT04451954
View directory record Official record
Conditions
Influenza Immunisation, Healthy Volunteers
Interventions
Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 2 and adjuvant, Quadrivalent RIV with 2018-2019 NH H3 strain, Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
San Diego, California • Melbourne, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

NCT00719043
View directory record Official record
Conditions
Influenza
Interventions
A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
841 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
10
States / cities
Denver, Colorado • Chicago, Illinois • Metairie, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination

NCT00889889
View directory record Official record
Conditions
Influenza
Interventions
Cell-Derived Trivalent Subunit Influenza Vaccine, Placebo
Biological
Lead sponsor
Abbott Biologicals
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
15
States / cities
Jacksonville, Florida • Pembroke Pines, Florida • South Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

NCT02876159
View directory record Official record
Conditions
Influenza
Interventions
2016-2017 Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
20 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 11, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

NCT02274545
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
H7N9 Anhui 2013/AA ca, Inactivated subvirion H7N9 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
50 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 11, 2026, 5:01 PM EDT